DiosCURE is developing next-generation immunotherapies focused on a novel approach against SARS-CoV-2. The Company’s proprietary bi- and trivalent variable domains of heavy chain-only antibodies (VHHs) are synergistic combinations of single-domain antibodies, constructed following structural information and optimized for potency as well as their potential to avoid the emergence of escape mutants. DiosCURE designed lead candidates that target two different epitopes of the SARS-CoV-2 spike protein with the potential to be highly efficacious, well-tolerated and manufactured at a large-scale standardized process.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Siemensstraße 10, Bonn,nordrhein-Westfalen 53121,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.dioscure.com
- Keywords
- IT Consulting.
- HQ
- Bonn, Nordrhein-Westfalen
Dioscure Therapeutics Questions
Dioscure Therapeutics's website is http://www.dioscure.com
Dioscure Therapeutics's LinkedIn profile is https://de.linkedin.com/company/dioscure-therapeutics
Dioscure Therapeutics has
2 employees.
View email and phone details for 2
employees at Dioscure Therapeutics.
Dioscure Therapeutics's industry is
Biotechnology Research
Dioscure Therapeutics's top competitors are
Northern Data Group,
Acus Laboratories Gmbh,
Exaloan Ag,
Centre Of Molecular Inflammation Research, Cemir,
Arzeda,
Odyssey Therapeutics,
Gleichstrom Gmbh,
Life Science Inkubator Gmbh,
Stiftung Ahrtal,
Theraimmune Gmbh.
Dioscure Therapeutics's categories are Biotechnology Research
Dioscure Therapeutics's founding year is 2020
